Vaccinex Statistics
Total Valuation
Vaccinex has a market cap or net worth of $10.12 million. The enterprise value is $8.74 million.
Important Dates
The last earnings date was Thursday, November 14, 2024, after market close.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Vaccinex has 2.80 million shares outstanding. The number of shares has increased by 480.32% in one year.
| Current Share Class | 2.80M |
| Shares Outstanding | 2.80M |
| Shares Change (YoY) | +480.32% |
| Shares Change (QoQ) | +11.52% |
| Owned by Insiders (%) | 0.38% |
| Owned by Institutions (%) | 1.08% |
| Float | 1.11M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 14.33 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 22.52 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.77
| Current Ratio | 0.77 |
| Quick Ratio | 0.63 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -342.96% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | $9,700 |
| Profits Per Employee | -$464,425 |
| Employee Count | 40 |
| Asset Turnover | 0.10 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -70.62% in the last 52 weeks. The beta is 0.98, so Vaccinex's price volatility has been similar to the market average.
| Beta (5Y) | 0.98 |
| 52-Week Price Change | -70.62% |
| 50-Day Moving Average | 3.29 |
| 200-Day Moving Average | 5.76 |
| Relative Strength Index (RSI) | 55.36 |
| Average Volume (20 Days) | 115,385 |
Short Selling Information
The latest short interest is 127,496, so 4.56% of the outstanding shares have been sold short.
| Short Interest | 127,496 |
| Short Previous Month | 34,501 |
| Short % of Shares Out | 4.56% |
| Short % of Float | 11.54% |
| Short Ratio (days to cover) | 0.74 |
Income Statement
In the last 12 months, Vaccinex had revenue of $388,000 and -$18.58 million in losses. Loss per share was -$12.02.
| Revenue | 388,000 |
| Gross Profit | -16.19M |
| Operating Income | -20.34M |
| Pretax Income | -19.19M |
| Net Income | -18.58M |
| EBITDA | -20.23M |
| EBIT | -20.34M |
| Loss Per Share | -$12.02 |
Full Income StatementBalance Sheet
The company has $2.91 million in cash and $59,000 in debt, giving a net cash position of $2.85 million or $1.02 per share.
| Cash & Cash Equivalents | 2.91M |
| Total Debt | 59,000 |
| Net Cash | 2.85M |
| Net Cash Per Share | $1.02 |
| Equity (Book Value) | -1.32M |
| Book Value Per Share | -1.09 |
| Working Capital | -1.42M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$15.85 million and capital expenditures -$22,000, giving a free cash flow of -$15.87 million.
| Operating Cash Flow | -15.85M |
| Capital Expenditures | -22,000 |
| Free Cash Flow | -15.87M |
| FCF Per Share | -$5.68 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -5,241.24% |
| Pretax Margin | -4,787.89% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -13,583.87% |